(Press-News.org) NEW YORK (Dec. 10, 2012) -- Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL (ABC-DLBCL), remains a major therapeutic challenge. An international research team, led by two laboratories from Weill Cornell Medical College, has developed a new experimental drug therapy to target this aggressive form of lymphoma.
In the journal Cancer Cell, researchers report the discovery of an experimental small molecule agent, MI-2, that irreversibly inactivates MALT1 -- a key protein responsible for driving the growth and survival of ABC-DLBCL cells.
"In our study we show the drug MI-2 we developed inactivates any MALT1 protein it touches, and without any apparent toxicity in animal models," says the study's lead investigator, Dr. Ari Melnick, associate professor of medicine and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell Medical College.
The research team, which includes investigators from Spain, Canada and several other U.S. institutions, are now working to optimize the drug while testing MI-2 with other drug therapies that could be less toxic than current chemotherapy regimens.
"No single drug can cure lymphoma. This is why we need to combine agents that can strike-out the different cellular pathways that lymphoma cells use to survive," says Dr. Melnick, who is also a hematologist-oncologist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. "We want to eliminate the use of toxic chemotherapy in the treatment of lymphoma patients, and these new study findings take us one-step closer to our goal of creating effective combinational molecular targeted therapy regimens to reduce treatment toxicity and improve lymphoma patient outcomes."
"A Bona Fide Therapeutic Target"
MALT1 is highly active in ABC-DLBCL and plays an important role in lymphoma cancer cell growth and survival. The unique protein is the only paracaspase produced in humans --and is a particular type of protease protein that cuts apart other proteins. But when MALT1 slices proteins in ABC-DLBCLs, it activates growth-promoting molecules and stops the work of other proteins that inhibit that growth.
"In essence, MALT1 turns off the brakes and presses the gas pedal to accelerate cell growth and survival in this aggressive cancer," Dr. Melnick says.
In this study, the researchers developed an activated form of MALT1 in the test tube that allowed them to study the structure of the molecule, and search for small molecule agents to shut it down. The key insights enabling this technical feat were achieved by co-lead investigator Dr. Hao Wu, an expert in biochemistry and structural biology and a former faculty member at Weill Cornell who is now at Harvard Medical School.
The researchers screened libraries of chemicals until they found one that tightly bonded to MALT1, preventing it from cutting other proteins. The agent, MI-2, also inactivated MALT1 in human samples of ABC-DLBCL, according to researchers.
When they tested the agent in mice, the research team found it stopped cancer growth without toxicity in normal tissues -- a trait Dr. Melnick says is due to the fact that MALT1 is not required for biological processes essential for life.
If tested successfully in human clinical trials, MI-2 could have benefits for other diseases, including MALT1 lymphoma, a lower-grade type of lymphoma. It could also possibly play a role in a variety of inflammatory and autoimmune disorders.
"MALT1 is a bona fide therapeutic target, and with the discovery of MI-2 we have provided a lead compound that forms the basis of a new class of therapeutic agents," says Dr. Melnick.
The Cornell Center for Technology Enterprise and Commercialization, on behalf of Cornell University, has filed a patent application on this research work.
INFORMATION:
This study was funded by the Leukemia & Lymphoma Society, Burroughs Wellcome Foundation, the Chemotherapy Foundation and the Beverly and Raymond Sackler Center for Physical and Biomedical Sciences at Weill Cornell Medical College.
Other study co-authors include Dr. Lorena Fontan, Dr. Chenghua Yang, Dr. Venkataraman Kabaleeswaran, Monica Garcia, Dr. Leandro Cerchietti, Dr. Rita Shaknovich, Shao Ning Yan and Dr. Fang Fang from Weill Cornell Medical College; Dr. Elena Beltran and Dr. Jose Angel Martinez-Climent from the University of Navarra, Spain; Dr. Katherine Borden, Dr. Laurent Volpon and Dr. Michael J. Osborne from the University of Montreal, Canada; Dr. Randy D. Gascoyne from the British Columbia Cancer Agency, Canada; and Dr. J. Fraser Glickman from The Rockefeller University.
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University's medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances -- including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson's disease, and most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston. For more information, visit weill.cornell.edu.
END
URBANA – Every year farmers spend a lot of money trying to control corn rootworm larvae, which are a significant threat to maize production in the United States and, more recently, in Europe. University of Illinois researchers have been working on validating a model for estimating damage functions.
Nicholas Tinsley, a doctoral candidate in crop sciences, has refined a model developed in 2009 by researchers at the University of Wisconsin and in Brescia, Italy, to describe the relationship between root injury caused by these pests and yield loss. He used the equivalent ...
DETROIT - Both nature and nurture appear to be significant factors in early antisocial behaviors of adopted children, a Wayne State University researcher believes.
Christopher Trentacosta, Ph.D., assistant professor of psychology in the College of Liberal Arts and Sciences, recently examined data from 361 linked triads (birth mother, adoptive parents, adopted child) in order to assess externalizing behavioral problems such as aggression and defiance when children were 18, 27 and 54 months of age.
The triads were part of the Early Growth and Development Study (EGDS), ...
CHAMPAIGN, Ill. — The small kerosene lamps that light millions of homes in developing countries have a dark side: black carbon – fine particles of soot released into the atmosphere.
New measurements show that kerosene wick lamps release 20 times more black carbon than previously thought, say researchers at the University of Illinois and the University of California, Berkeley. The group published its findings in the journal Environmental Science and Technology.
Black carbon is a hazard for human health and the environment, affecting air quality both indoors and out. ...
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.
The trial leaders will present the results of the Dana-Farber Cancer Institute ALL Consortium study, which involved nearly 500 patients under age 18 with B-precursor acute lymphoblastic leukemia (B-ALL), at the annual meeting of the American Society of Hematology ...
Over past decades, many areas of the forested Amazon basin have become a patchwork of farms, pastures and second-growth forest as people have moved in and cleared land--but now many are moving out, in search of economic opportunities in newly booming Amazonian cities. The resulting depopulation of rural areas, along with spreading road networks and increased drought are causing more and bigger fires to ravage vast stretches, say researchers in a new study. The study, focusing on the Peruvian Amazon, is the latest to suggest that land-use changes and other factors, including ...
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.
In a study of 315 patients from a German database, researchers from Dana-Farber Cancer Institute found that serum galectin-1 levels "are significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."
The measurements were made ...
When it comes to climate change, deforestation and toxic waste, the assumption has been that conservative views on these topics are intractable. But new research from the University of California, Berkeley, suggests that such viewpoints can be changed after all, when the messages about the need to be better stewards of the land are couched in terms of fending off threats to the "purity" and "sanctity" of Earth and our bodies.
A UC Berkeley study has found that while people who identified themselves as conservatives tend to be less concerned about the environment than ...
Violent acts in James Bond films were more than twice as common in Quantum of Solace (2008) than in the original 1962 movie Dr No, researchers from New Zealand's University of Otago have found.
The researchers analysed 22 official franchise films, which span 46 years, to test the hypothesis that popular movies are becoming more violent (The latest Bond film, Skyfall, was not included as it was unreleased at the time of the study).
They found that rates of violence increased significantly over the period studied and there was an even bigger increase in portrayals of ...
Infrared data from NASA's Aqua satellite have watched the strong thunderstorms in Typhoon Bopha fizzle and shrink in area over the weekend as wind shear increased. Bopha has now dissipated in the South China Sea, just west of Luzon, Philippines.
NASA's Aqua satellite has been providing data on Bopha since the day it formed on Nov. 26. In the storm's last days, Aqua's Atmospheric Infrared Sounder (AIRS) instrument captured infrared data of the storm and showed that cloud top temperatures warmed from Dec. 8 through Dec. 9 as cloud heights fell and thunderstorms lost their ...
NASA's Aqua satellite got "eyeballed" from Cyclone Claudia in the Southern Indian Ocean when two instruments captured the storm's eye in infrared and visible light. Satellite data indicates that Claudia's eye is about 10 nautical miles wide.
On Dec. 10 at 0841 UTC (3:41 a.m. EST), NASA's Aqua satellite's Atmospheric Infrared Sounder (AIRS) instrument captured an infrared view of Cyclone Claudia which showed a clear eye surrounded by powerful thunderstorms. The thunderstorms that surrounded the eye were high in the troposphere and cloud top temperatures topped -63 Fahrenheit ...
